At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 11, 2026 at 07:03 ET
Syndax presented 12 abstracts on revumenib at EHA 2026, including real-world data showing 82% ORR in R/R NPM1m/KMT2Ar patients, a Phase 1 frontline combo trial with 97% CRc, and the SAVE trial with 88% ORR. The data reinforce revumenib's broad activity across multiple acute leukemia subtypes and settings, supporting its commercial potential and ongoing pivotal trials.
- Real-world ROAR study: 82% ORR (9/11) and 64% CR/CRh (7/11) in R/R NPM1m or KMT2Ar acute leukemia.
- Phase 1 frontline combo: 97% CRc (34/35) and 86% MRD negativity (25/29) in newly diagnosed NPM1m/KMT2Ar AML.
- SAVE trial (R/R): 88% ORR (37/42), 68% MRD negativity (25/37) among responders, 45% transplant rate (19/42).
- Post-hoc AUGMENT-101: 95% estimated 12-month OS in patients resuming revumenib post-HSCT.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access